CARsgen Therapeutics Holdings Limited
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China. Its products include CT053 for the treatment of relapsed/refractory multiple myeloma (R/R MM). The company is also developing… Read more
CARsgen Therapeutics Holdings Limited (CRTHF) - Total Liabilities
Latest total liabilities as of April 2025: $551.26 Million USD
Based on the latest financial reports, CARsgen Therapeutics Holdings Limited (CRTHF) has total liabilities worth $551.26 Million USD as of April 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
CARsgen Therapeutics Holdings Limited - Total Liabilities Trend (2014–2024)
This chart illustrates how CARsgen Therapeutics Holdings Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
CARsgen Therapeutics Holdings Limited Competitors by Total Liabilities
The table below lists competitors of CARsgen Therapeutics Holdings Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Satellogic V Inc
NASDAQ:SATL
|
USA | $127.76 Million |
|
Longxing Chemical Stock Co Ltd
SHE:002442
|
China | CN¥2.67 Billion |
|
ShaMaran Petroleum Corp
PINK:SHASF
|
USA | $202.31 Million |
|
AXISCADES Technologies Limited
NSE:AXISCADES
|
India | ₹5.20 Billion |
|
Jayaswal Neco Industries Limited
NSE:JAYNECOIND
|
India | ₹30.60 Billion |
|
Solaris Resources Inc.
OTCQB:SLSR
|
USA | $102.01 Million |
|
Era Co Ltd
SHE:002641
|
China | CN¥2.73 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down CARsgen Therapeutics Holdings Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.45 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.57 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CARsgen Therapeutics Holdings Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CARsgen Therapeutics Holdings Limited (2014–2024)
The table below shows the annual total liabilities of CARsgen Therapeutics Holdings Limited from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-10-31 | $616.33 Million | +35.30% |
| 2023-10-31 | $455.51 Million | +57.27% |
| 2022-10-31 | $289.64 Million | -43.09% |
| 2021-10-31 | $508.98 Million | -82.63% |
| 2020-10-31 | $2.93 Billion | +319.29% |
| 2018-10-31 | $698.80 Million | +5.86% |
| 2017-10-31 | $660.10 Million | -4.91% |
| 2016-10-31 | $694.20 Million | +11.66% |
| 2015-10-31 | $621.70 Million | +9.49% |
| 2014-10-31 | $567.80 Million | -- |